Log in

NASDAQ:INGN - Inogen Stock Price, Forecast & News

$44.13
-0.72 (-1.61 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$43.93
Now: $44.13
$45.06
50-Day Range
$44.13
MA: $50.41
$66.69
52-Week Range
$41.19
Now: $44.13
$146.89
Volume247,959 shs
Average Volume263,190 shs
Market Capitalization$970.86 million
P/E Ratio30.65
Dividend YieldN/A
Beta1.69
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Read More…

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INGN
CUSIPN/A
Phone805-562-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$358.11 million
Cash Flow$2.91 per share
Book Value$14.54 per share

Profitability

Net Income$51.85 million

Miscellaneous

Employees1,099
Market Cap$970.86 million
Next Earnings Date2/25/2020 (Confirmed)
OptionableOptionable

Receive INGN News and Ratings via Email

Sign-up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter.


Inogen (NASDAQ:INGN) Frequently Asked Questions

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

How were Inogen's earnings last quarter?

Inogen Inc (NASDAQ:INGN) announced its earnings results on Tuesday, November, 5th. The medical technology company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. The medical technology company earned $91.76 million during the quarter, compared to analysts' expectations of $91.65 million. Inogen had a return on equity of 9.89% and a net margin of 8.76%. Inogen's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period last year, the business posted $0.73 EPS. View Inogen's Earnings History.

When is Inogen's next earnings date?

Inogen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Inogen.

How can I listen to Inogen's earnings call?

Inogen will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Inogen issued on next quarter's earnings?

Inogen issued an update on its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $361.4-362.4 million, compared to the consensus revenue estimate of $372.96 million.

What price target have analysts set for INGN?

7 analysts have issued 1-year target prices for Inogen's shares. Their forecasts range from $47.00 to $90.00. On average, they expect Inogen's stock price to reach $65.00 in the next year. This suggests a possible upside of 47.3% from the stock's current price. View Analyst Price Targets for Inogen.

What is the consensus analysts' recommendation for Inogen?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inogen.

Has Inogen been receiving favorable news coverage?

News coverage about INGN stock has trended very negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Inogen earned a media sentiment score of -3.4 on InfoTrie's scale. They also assigned news stories about the medical technology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Inogen.

Who are some of Inogen's key competitors?

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), First Solar (FSLR), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU) and Dynavax Technologies (DVAX).

Who are Inogen's key executives?

Inogen's management team includes the folowing people:
  • Mr. Scott Wilkinson, CEO, Pres & Director (Age 54)
  • Mr. Brenton Taylor, Co-founder & Exec. VP of Engineering (Age 38)
  • Ms. Alison Perry Bauerlein, Co-founder, Exec. VP of Fin., CFO, Corp. Sec. & Treasurer (Age 38)
  • Mr. Bart Sanford, Exec. VP of Operations (Age 53)
  • Mr. Byron Myers, Exec. VP of Sales & Marketing (Age 40)

Who are Inogen's major shareholders?

Inogen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (4.44%), AQR Capital Management LLC (3.92%), State Street Corp (3.00%), New York State Common Retirement Fund (2.25%), Rockefeller Capital Management L.P. (1.28%) and Riverbridge Partners LLC (1.23%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.

Which major investors are selling Inogen stock?

INGN stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Renaissance Technologies LLC, Cubist Systematic Strategies LLC, UBS Asset Management Americas Inc., State Street Corp, Marshall Wace LLP, American International Group Inc. and AlphaCrest Capital Management LLC. View Insider Buying and Selling for Inogen.

Which major investors are buying Inogen stock?

INGN stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Point72 Asset Management L.P., Beacon Investment Advisory Services Inc., Tamarack Advisers LP, Great West Life Assurance Co. Can, Jane Street Group LLC, Pinebridge Investments L.P. and Oxford Asset Management LLP. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch and Loren L Mcfarland. View Insider Buying and Selling for Inogen.

How do I buy shares of Inogen?

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Inogen's stock price today?

One share of INGN stock can currently be purchased for approximately $44.13.

How big of a company is Inogen?

Inogen has a market capitalization of $970.86 million and generates $358.11 million in revenue each year. The medical technology company earns $51.85 million in net income (profit) each year or $2.30 on an earnings per share basis. Inogen employs 1,099 workers across the globe.View Additional Information About Inogen.

What is Inogen's official website?

The official website for Inogen is http://www.inogen.com/.

How can I contact Inogen?

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]


MarketBeat Community Rating for Inogen (NASDAQ INGN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  360 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  592
MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote "Outperform" if you believe INGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: What is a balanced fund?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel